Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15401891 | 1.00 | AKT1 (0.39) | AKT1AKT2 | |
| SCHEMBL15401382 | 0.76 | TAAR1 (0.39) | AKT1AKT2 | |
| SCHEMBL15401384 | 0.76 | TAAR1 (0.39) | AKT1AKT2 | |
| SCHEMBL15906512 | 0.72 | F11 (0.40) | AKT1AKT2 | |
| SCHEMBL10241861 | 0.71 | CYP2A6 (0.35) | — | |
| SCHEMBL1539148 | 0.69 | KDM1A (0.40) | AKT1AKT2 | |
| SCHEMBL10226674 | 0.69 | KDM1A (0.40) | AKT1AKT2 | |
| SCHEMBL1608039 | 0.69 | KDM1A (0.40) | AKT1AKT2 | |
| SCHEMBL11950297 | 0.69 | KMT2A (0.35) | — | |
| SCHEMBL991567 | 0.69 | CYP2A6 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2868660-B1 | ANTITUMOR EFFECT POTENTIATOR COMPRISING AN IMIDAZOOXAZINE COMPOUND | TAIHO PHARMACEUTICAL CO LTD (JP) | 2017-12-27 | — | — | EP | disclosed |
| US-9375434-B2 | Antitumor effect potentiator composed of imidazooxazine compound | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2016-06-28 | — | — | US | disclosed |
| US-9289431-B2 | — | — | 2016-03-22 | — | — | US | disclosed |
| EP-2698372-B1 | NOVEL IMIDAZO-OXAZINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2016-02-03 | — | — | EP | disclosed |
| US-20150164909-A1 | ANTITUMOR EFFECT POTENTIATOR COMPOSED OF IMIDAZOOXAZINE COMPOUND | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2015-06-18 | — | — | US | disclosed |
| EP-2868660-A1 | ANTITUMOR EFFECT POTENTIATOR COMPOSED OF IMIDAZOOXAZINE COMPOUND | Taiho Pharmaceutical Co., Ltd. (JP) | 2015-05-06 | — | — | EP | disclosed |
| US-8772283-B2 | Imidazo-oxazine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2014-07-08 | — | — | US | disclosed |
| EP-2698372-A1 | NOVEL IMIDAZO-OXAZINE COMPOUND OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2014-02-19 | — | — | EP | disclosed |
| US-20140005185-A1 | NOVEL IMIDAZO-OXAZINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2014-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150164909-A1 | ANTITUMOR EFFECT POTENTIATOR COMPOSED OF IMIDAZOOXAZINE COMPOUND | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS, TPD52L2 | AKT1 419/4885AKT2 620/4885 |
| US-20140005185-A1 | NOVEL IMIDAZO-OXAZINE COMPOUND OR SALT THEREOF | IKZF3, IKZF2, IKZF1 | AKT1 2351/4885AKT2 1971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.